Audit of Antipsychotic Polypharmacy in Christchurch

Abstract

Get full access to this article

View all access options for this article.

References

1. Taylor

Paton

Kerwin

. The Maudsley Prescribing Guidelines9th edn. Informa Healthcare, London 2007.

2. National Institute of Clinical Excellence. Guidance on the Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Health Technology Appraisal No 43. Available from URL: www.nice.org.uk , 2002.

3. Tranulis

Skalli

Lalonde

Nicole

Stip

. Benefits and risks of antipsychotic polypharmacy. An evidence based review of the literature. Drug Safety 2008; 31: 7–20.

4. Waddington

Youseff

Kinsella

. Mortality in schizophrenia. antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry 1998; 173: 325–329.

5. Connolly

Taylor

. Ethnicity and quality of antipsychotic prescribing among in-patients in south London. British Journal of Psychiatry 2008; 193: 161–162.

6. Kuno

Rothbard

. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry 2002; 159: 567–572.